An article mesothelioma recently published in scientific journals Lung Cancer that investigates the benefits and the cost of the combination of cisplatin and Pemetrexed with carboplatin and Pemetrexed for chemotherapy mesothelioma .
Chemotherapy combination of cisplatin and Pemetrexed is one of several choices of chemotherapy that has proven quite successful in the treatment of patients with mesothelioma pleural malignant / malignant pleural mesothelioma (MPM), but this combination can be very toxic to the body. There is no treatment and treatment for cancer mesothelioma malignant without any side effects that are not desired.
In the journal the researchers noted that "there are two phases of the study randomized phase III showed significant benefits for the prognosis of mesothelioma with the use of antifolates such as raltitrexed or Pemetrexed, when combined with cisplatin. The study has demonstrated increased absolute survival overall average of 2.6 and 2.8 months, compared with the treatment of single to cisplatin. This makes a lot of institutions using cisplatin and Pemetrexed as a standard treatment of chemotherapy palliation for malignant pleural mesothelioma . "
Unfortunately, the combination of cisplatin and Pemetrexed produce effects toxic undesirable and has led many researchers to study the chemotherapy drugs other combination with Pemetrexed. The researchers said, "Recently, two experimental phase II has been evaluated will be the efficacy of carboplatin and Pemetrexed in MPM. Both studies showed response rates overall 18.6 and 25%, with a survival rate average of 12.7 and 14 months. As a continuation of these results, we conducted a retrospective analysis in patients with MPM who were treated with carboplatin and Pemetrexed in our institution. "
In an effort to find a combination of chemotherapy mesothelioma with minimal toxicity and side effects, the researchers investigated further by replacing cisplatin with carboplatin when paired with Pemetrexed. Using a retrospective approach, researchers evaluated 49 cases of mesothelioma pleural malignant with a combination of carboplatin and Pemetrexed and compare the results with the data of combination chemotherapy, cisplatin with Pemetrexed.
Level of disease control (known in the absence of signs of progressive mesothelioma by CT scan) for patients is 69 percent, and the response of the partial and the percentage of stable disease by 28 percent and 41 percent. Improved clinical as shown in figure 69 percent, the majority of patients reported increased profits after two cycles of chemotherapy. Toxicity is generally low and better than the toxicity of cisplatin with Pemetrexed.
The average time of treatment failure was 4.6 months. Average survival as a whole in this study is 14 months, compared with cisplatin-pemetrexed for 12.1 months. Researchers argued, "In conclusion, our data show the combination carboplatin and Pemetrexed may be an option in the treatment of mesothelioma , particularly in patients who experience problems with the use of cisplatin. "
